stoxline Quote Chart Rank Option Currency Glossary
  
AN2 Therapeutics, Inc. (ANTX)
3.0293  -0.101 (-3.22%)    02-27 14:07
Open: 3.16
High: 3.16
Volume: 505,098
  
Pre. Close: 3.13
Low: 3.02
Market Cap: 90(M)
Technical analysis
2024-02-27 1:42:11 PM
Short term     
Mid term     
Targets 6-month :  16.79 1-year :  24.99
Resists First :  14.37 Second :  21.39
Pivot price 7.99
Supports First :  3.01 Second :  2.51
MAs MA(5) :  3.18 MA(20) :  11
MA(100) :  16.21 MA(250) :  12.11
MACD MACD :  -4.5 Signal :  -3.9
%K %D K(14,3) :  0.1 D(3) :  0.3
RSI RSI(14): 13.4
52-week High :  22.21 Low :  3.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ANTX ] has closed above bottom band by 32.9%. Bollinger Bands are 397.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.34 - 3.36 3.36 - 3.38
Low: 3.04 - 3.06 3.06 - 3.08
Close: 3.1 - 3.13 3.13 - 3.16
Company Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Headline News

Fri, 23 Feb 2024
Should You Accumulate AN2 Therapeutics Inc (ANTX) Stock Friday Morning? - InvestorsObserver

Tue, 20 Feb 2024
Premarket Mover: AN2 Therapeutics Inc (ANTX) Down 3.30% - InvestorsObserver

Thu, 15 Feb 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc ... - PR Newswire

Tue, 13 Feb 2024
AN2 Therapeutics stock falls as Leerink cuts on trial setback - Seeking Alpha

Mon, 12 Feb 2024
AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost ... - GlobeNewswire

Mon, 12 Feb 2024
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market ... - Markets Insider

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 30 (M)
Shares Float 11 (M)
Held by Insiders 25.4 (%)
Held by Institutions 69.2 (%)
Shares Short 280 (K)
Shares Short P.Month 294 (K)
Stock Financials
EPS -2.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.67
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30 %
Return on Equity (ttm) -48.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow -21 (M)
Stock Valuations
PE Ratio -1.09
PEG Ratio 0
Price to Book value 0.65
Price to Sales 0
Price to Cash Flow -2.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android